Sachpekidis Christos, Kopp-Schneider Annette, Merz Maximilian, Jauch Anna, Raab Marc-Steffen, Goldschmidt Hartmut, Dimitrakopoulou-Strauss Antonia
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, 69120 Heidelberg, Germany.
Department of Biostatistics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Cancers (Basel). 2020 May 23;12(5):1335. doi: 10.3390/cancers12051335.
There is an unmet need for positron emission tomography (PET) radiotracers that can image bone disease in multiple myeloma (MM) in a more sensitive and specific way than the widely used F-fluorodeoxyglucose (F-FDG). Sodium fluoride (F-NaF) is a highly sensitive tracer of bone reconstruction, evolving as an important imaging agent for the assessment of malignant bone diseases. We attempted to investigate for the first time the prognostic significance of F-NaF PET/CT in newly diagnosed, symptomatic MM patients planned for autologous stem cell transplantation (ASCT). Forty-seven patients underwent dynamic and static PET/CT with F-NaF before treatment. After correlation with the respective findings on CT and F-FDG PET/CT that served as reference, the F-NaF PET findings were compared with established factors of high-risk disease, like cytogenetic abnormalities as well as bone marrow plasma cell infiltration rate. Furthermore, the impact of F-NaF PET/CT on progression-free survival (PFS) was analyzed. Correlation analysis revealed a moderate, significant correlation of the F-NaF parameters SUV and K in reference tissue with bone marrow plasma cell infiltration rate. However, no significant correlation was observed regarding all other F-NaF PET parameters. Survival analysis revealed that patients with a pathologic F-NaF PET/CT have a shorter PFS (median = 36.2 months) than those with a physiologic scan (median = 55.6 months) ( = 0.02). Nevertheless, no quantitative F-NaF parameter could be shown to adversely affect PFS. In contrast, the respective analysis for quantitative dynamic F-FDG PET/CT revealed that the parameters SUV, fractional blood volume (V), k and influx from reference tissue as well as SUV from MM lesions had a significant negative impact on patient survival. The herein presented findings highlight the rather limited role of F-NaF PET/CT as a single PET approach in MM.
对于正电子发射断层扫描(PET)放射性示踪剂存在未满足的需求,这些示踪剂能够以比广泛使用的F-氟脱氧葡萄糖(F-FDG)更敏感、更特异的方式对多发性骨髓瘤(MM)中的骨病进行成像。氟化钠(F-NaF)是骨重建的高灵敏度示踪剂,正逐渐成为评估恶性骨病的重要成像剂。我们首次试图研究F-NaF PET/CT在计划进行自体干细胞移植(ASCT)的新诊断、有症状MM患者中的预后意义。47例患者在治疗前接受了F-NaF动态和静态PET/CT检查。在与作为参考的CT和F-FDG PET/CT的各自结果进行关联后,将F-NaF PET结果与高危疾病的既定因素(如细胞遗传学异常以及骨髓浆细胞浸润率)进行比较。此外,分析了F-NaF PET/CT对无进展生存期(PFS)的影响。相关性分析显示,参考组织中F-NaF参数SUV和K与骨髓浆细胞浸润率呈中度显著相关。然而,在所有其他F-NaF PET参数方面未观察到显著相关性。生存分析显示,PET/CT结果为病理性的患者的PFS(中位数 = 36.2个月)短于PET/CT结果为生理性的患者(中位数 = 55.6个月)(P = 0.02)。然而,没有定量F-NaF参数显示对PFS有不利影响。相比之下,对定量动态F-FDG PET/CT的相应分析显示,参数SUV、血容量分数(V)、k以及参考组织的流入量以及MM病变处的SUV对患者生存有显著负面影响。本文呈现的研究结果突出了F-NaF PET/CT作为MM单一PET方法的作用相当有限。